Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Turkish Validity and Reliability of SGRQ-I

Turkish Validity and Reliability of the Saint George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary fibrosis patients, is not available. There is no commonly used quality of life questionnaire in patients with idiopathic pulmonary fibrosis. The aim of the study is to translate and validate the SGRQ idiopathic pulmonary fibrosis version of questionnaire into Turkish.

Who May Be Eligible (Plain English)

Who May Qualify: - Be over 18 years old - Having a Diagnosis of Idiopathic Pulmonary Fibrosis - To be literate in Turkish Who Should NOT Join This Trial: - Exacerbation or exacerbation in the last 6 weeks - Presence of comorbidities affecting ambulation - Cognitive impairment Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Be over 18 years old * Having a Diagnosis of Idiopathic Pulmonary Fibrosis * To be literate in Turkish Exclusion Criteria: * Exacerbation or exacerbation in the last 6 weeks * Presence of comorbidities affecting ambulation * Cognitive impairment

Treatments Being Tested

OTHER

Questionnaire

Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study. The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician.

Locations (1)

Esra Pehlivan
Istanbul, Üsküdar, Turkey (Türkiye)